Philip’s 22-year career in machine learning started with an AI powered screening for dyslexia, back in 2000. More recently Philip helped pioneer the use of AI in diagnostic screening Software as a Medical Device. In that work Philip designed and developed one of the world’s most accurate, non-invasive screening tools for breast cancer, successfully regulated by the FDA for commercial clinical use in 2020. At AstraZeneca, Philip leads a Computer Vision team in the company’s center of excellence for AI and sits on various advisory groups including the Responsible AI Community of Practice Steering Committee and the Software as a Medical Device Taskforce.